Company / Operating Income
ADMA Biologics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$191.4M
FY2025
5-year range
-$58.4M / $191.4M
FY2021-FY2025
Trend
+37.7%
vs FY2024
Sector context
#27 of 204
Health Care
What the data says
ADMA Biologics, Inc.'s operating income of $191M is higher than 87% of companies in the Health Care sector (FY2025). Operating Income has increased for 5 consecutive years, from -$65M in FY2020 to $191M in FY2025.
Based on SEC 10-K filings.
$191M in FY2025. Top quartile in the Health Care sector.
Improved from $22M to $191M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 204This company $191.4M Sector average $107.8M
▼
+77.7% above sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s operating income has grown for 5 consecutive years.
- In FY2025, operating income increased 37.7% year-over-year.
- Ranks #27 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $191.4M | +37.7% |
| FY2024 | $139.0M | +542.5% |
| FY2023 | $21.6M | +137.1% |
| FY2022 | -$58.4M | +0.0% |
| FY2021 | -$58.4M | +10.1% |
| FY2020 | -$64.9M | -56.7% |
| FY2019 | -$41.4M | +31.3% |
| FY2018 | -$60.3M | -247.9% |
| FY2017 | -$17.3M | +0.0% |
| FY2016 | -$17.3M | -8.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026